In advanced knee osteoarthritis, platelet-rich plasma is best understood as a bridge therapy prior to arthroplasty rather than a replacement for it. That is the framing the trial authors themselves used: in a randomized controlled trial of 90 patients aged 40 to 80 with symptomatic Kellgren-Lawrence grade 3 to 4 knee osteoarthritis who were already on arthroplasty waiting lists, two PRP injections produced greater six-month clinical and biomarker improvement than corticosteroid or NSAID controls, and the authors concluded that this supports PRP as a safe bridge therapy prior to arthroplasty [1]. It is a way to hold pain and function while the decision about surgery is made, not a way to avoid making it.
That distinction is the whole article. Everything below is about how to tell whether a bridge is working for you and what happens when it is not.
What the late-stage trial actually measured
The 90 patients were randomized to two autologous PRP injections one week apart, a single betamethasone injection, or aceclofenac tablets, with outcomes collected at baseline, three months, and six months. Eighty-two patients completed six-month follow-up [1].
PRP produced significant and sustained reductions in visual analog scale pain scores at three and six months compared with baseline and with both control groups. Total and subscale WOMAC scores — pain, stiffness, and function — improved significantly only in the PRP group at both follow-up points [1].
The opioid finding
Opioid consumption was significantly lower in the PRP group than in the corticosteroid and NSAID groups at three months, and lower than in the corticosteroid group at six months [1]. Adverse events in the PRP group were mild and transient.
What it did not measure
The trial followed patients for six months. It reports pain, function, opioid use, and serum biomarkers of inflammation and cartilage turnover. It does not tell you what happens at two years, and it does not report joint imaging.
Why nobody should promise you structural repair
The RESTORE randomized clinical trial compared intra-articular PRP with saline placebo in patients with symptomatic knee osteoarthritis and radiographic changes, and found no significant difference between groups in medial tibial cartilage volume on MRI at 12 months [2]. That result is why we describe PRP in terms of symptoms and function and never in terms of rebuilding the joint surface.
Holding those two trials together is not a contradiction. A treatment can meaningfully change what a joint feels like over months without changing what it looks like on imaging, and a patient deserves to be told which of those two things is being offered.
How the broader evidence reads
A 2025 systematic review and meta-analysis of 21 randomized controlled trials, covering 2,406 participants with knee osteoarthritis, found significant improvement in visual analog scale and WOMAC scores with intra-articular PRP compared with placebo, though not in KOOS scores [3]. Comparisons against corticosteroid injection favored PRP across all pain scores in that analysis.
Preparation matters and is not standardized between practices, which is one reason results vary between studies. That variability is a reason to ask what is being prepared and how, not a reason to dismiss the category.
What a bridge plan looks like in practice
A bridge only makes sense if it is going somewhere. Before any injection we set out what the bridge is for — walking tolerance, stair tolerance, participation in rehabilitation, or time to plan an operation on your own schedule — and how we will know within a defined window whether it worked.
If the response is not enough, that is information rather than a failure, and it moves the conversation forward instead of repeating the same step. Where orthobiologics fit alongside the rest of the pathway is set out in our orthobiologics overview, including intraosseous and subchondral delivery and bone marrow aspirate concentrate.
When surgery is the right answer
Regen.MD provides surgery when conservative measures have been exhausted, and Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon. It is never the opening move, and a bridge therapy is not a reason to defer an operation you already need. Our conditions and surgical alternatives page describes how that sequence is decided.
Bring your imaging and your labs to a physician
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently asked questions
Does PRP rebuild the cartilage in a bone-on-bone knee?
No, and we do not present it that way. The RESTORE randomized trial found no significant difference in medial tibial cartilage volume on MRI at 12 months between intra-articular PRP and saline placebo in patients with symptomatic knee osteoarthritis. What the late-stage evidence supports is pain, stiffness, and function over a defined window, which is how we frame it in our evaluation and treatment approach.
If I am on a waiting list for knee replacement, is it too late for PRP?
That is precisely the population the late-stage trial studied: 90 patients aged 40 to 80 with Kellgren-Lawrence grade 3 to 4 knee osteoarthritis already on arthroplasty waiting lists. The authors concluded the results support PRP as a safe bridge therapy prior to arthroplasty, not as a replacement for it. Study summaries of this kind are collected in the library.
How long should I expect a bridge to hold?
The late-stage trial followed patients to six months and reported sustained improvement at that point; it does not answer what happens later. We set a review window before the injection so that the answer for you comes from your own tracked pain and function rather than from an average. The physician who reviews that with you is Dr. Gurpreet Singh Padda, MD, MBA, MHP.
Could peptides be used instead of an injection for an arthritic knee?
No. Peptides are discussed at Regen.MD as clinical and educational subjects, they are not sold, and nothing in the knee osteoarthritis evidence base positions them as an alternative to the treatments studied here. If you want to understand how they are handled in a physician-directed setting, see peptide and longevity medicine.
Sources
- Lacko M, Awad O, Matúška M, Strážik M, Barej J, et al. Intra-articular platelet-rich plasma demonstrates superior clinical and serum biomarker outcomes compared with corticosteroids and NSAIDs in late-stage knee osteoarthritis: a randomised controlled trial. Journal of Orthopaedic Surgery and Research. 2026;21(1):453. https://doi.org/10.1186/s13018-026-07013-w (referenced for: 90 patients aged 40–80 with KL grade 3–4 knee osteoarthritis on arthroplasty waiting lists; two PRP injections one week apart versus betamethasone or aceclofenac; 82 completed six-month follow-up; VAS and WOMAC outcomes; lower opioid consumption; mild and transient adverse events; the authors’ conclusion supporting PRP as a safe bridge therapy prior to arthroplasty).
- Bennell KL, Paterson KL, Metcalf BR, et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021;326(20):2021–2030. https://pmc.ncbi.nlm.nih.gov/articles/PMC8611484/ (referenced for: no significant difference in medial tibial cartilage volume on MRI at 12 months between PRP and saline placebo).
- Pelluri R, Sridevi B, Guntupalli C, et al. Effect of platelet-rich plasma versus placebo or corticosteroid for knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Orthopaedics and Trauma. 2025;62:102890. https://pmc.ncbi.nlm.nih.gov/articles/PMC11772150/ (referenced for: 21 randomized controlled trials, 2,406 participants; significant VAS and WOMAC improvement versus placebo; KOOS not significant; pain scores favoring PRP over corticosteroid).